share_log

Oppenheimer Assumes ESSA Pharma at Outperform, Announces Price Target of $17

Benzinga ·  Jun 26, 2023 06:48

Oppenheimer analyst Mark Breidenbach assumes ESSA Pharma (NASDAQ:EPIX) with a Outperform rating and announces Price Target of $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment